TGF-β Signaling Prevents MHC Class II–Expressing Lymphatic Endothelial Cells from Reactivating Human Allogenic Memory CD4+ T Cells
The Journal of Immunology · 2023
DOI: 10.4049/jimmunol.2200216 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Renata Mezyk-Kopec und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, HHS | NIH | National Cancer Institute.
Abstract (Originalsprache)
Lymphatic endothelial cells (LECs) express MHC class II (MHC-II) upon IFN-γ stimulation, yet recent evidence suggests that LECs cannot activate naive or memory CD4+ T cells. In this article, we show that IFN-γ–activated human dermal LECs can robustly reactivate allogeneic human memory CD4+ T cells (hCD4+ TMs), but only when TGF-β signaling is inhibited. We found that in addition to upregulating MHC-II, IFN-γ also induces LECs to upregulate glycoprotein A repetitions predominant, which anchors latent TGF-β to the membrane and potentially inhibits T cell activation. Indeed, hCD4+ TM proliferation was substantially increased when LEC-CD4+ TM cultures were treated with a TGF-β receptor type 1 inhibitor or when glycoprotein A repetitions predominant expression was silenced in LECs. Reactivated hCD4+ TMs were characterized by their proliferation, CD25 expression, and cytokine secretion. CD4+ TM reactivation was dependent on LEC expression of MHC-II, confirming direct TCR engagement. Although CD80 and CD86 were not detected on LECs, the costimulatory molecules OX40L and ICOSL were upregulated upon cytokine stimulation; however, blocking these did not affect CD4+ TM reactivation by LECs. Finally, we found that human dermal LECs also supported the maintenance of Foxp3-expressing hCD4+ TMs independently of IFN-γ–induced MHC-II. Together, these results demonstrate a role for LECs in directly modulating CD4+ TM reactivation under inflammatory conditions and point to LEC-expressed TGF-β as a negative regulator of this activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL.
- Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology Jagiellonian University, Krakow, Poland.
- Committee on Immunology, University of Chicago, Chicago, IL.
- Ben May Department of Cancer Research, University of Chicago, Chicago, IL.
ORCID-Profile: Lambert Potin, J Emiliano Gomez Medellin, Calixto M Salles
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- HHS | NIH | National Cancer Institute
Zitieren
APA
Mezyk-Kopec, R., Potin, L., Gomez Medellin, J. E., Salles, C. M., & Swartz, M. A. (2023). TGF-β Signaling Prevents MHC Class II–Expressing Lymphatic Endothelial Cells from Reactivating Human Allogenic Memory CD4+ T Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200216
Vancouver
Mezyk-Kopec R, Potin L, Gomez Medellin JE, Salles CM, Swartz MA. TGF-β Signaling Prevents MHC Class II–Expressing Lymphatic Endothelial Cells from Reactivating Human Allogenic Memory CD4+ T Cells. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200216
BibTeX
@article{MezykKopec2023,
author = {Mezyk-Kopec, Renata and Potin, Lambert and Gomez Medellin, J Emiliano and Salles, Calixto M and Swartz, Melody A},
title = {TGF-β Signaling Prevents MHC Class II–Expressing Lymphatic Endothelial Cells from Reactivating Human Allogenic Memory CD4+ T Cells},
journal = {The Journal of Immunology},
year = {2023},
doi = {10.4049/jimmunol.2200216}
}
EUVIMED